Literature DB >> 16465254

The tumor strikes back: new data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology.

P H Krammer.   

Abstract

Entities:  

Year:  1997        PMID： 16465254     DOI： 10.1038/sj.cdd.4400252

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  6 in total

1.  Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Authors:  Eiman Adel Hasby
Journal:  Pathol Oncol Res       Date:  2011-12-08       Impact factor: 3.201

Review 2.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

3.  Palmitoylation of human FasL modulates its cell death-inducing function.

Authors:  F Guardiola-Serrano; A Rossin; N Cahuzac; K Lückerath; I Melzer; S Mailfert; D Marguet; M Zörnig; A-O Hueber
Journal:  Cell Death Dis       Date:  2010-10-21       Impact factor: 8.469

4.  Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.

Authors:  U Ramp; M Dejosez; C Mahotka; B Czarnotta; T Kalinski; M Wenzel; I Lorenz; M Müller; P Krammer; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

Review 5.  The molecular genetics of cervical carcinoma.

Authors:  P A Lazo
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

6.  A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment.

Authors:  Raghu S Pandurangi; Marco Tomasetti; Sekar T Verapazham; Ramasamy Paulmurugan; Cynthia Ma; Sandeep Rajput; Manjushree Anjanappa; Harikrishna Nakshatri
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.